**Revenue by Segment:**
- Diagnostic devices: 60%
- Reagents and consumables: 30%
- Services: 10%

**TOP 3 Markets:**
- China: 45%
- Europe: 30%
- North America: 15%

Shenzhen YHLO Biotech Co., Ltd. generates the majority of its revenue from the sale of diagnostic devices, followed by reagents and consumables. Services account for a smaller portion of the total revenue.

The Chinese market is the largest for the company, attributed to its strong local presence and demand for diagnostic solutions. Europe and North America follow, with high demand for innovative diagnostic solutions in these regions.

**Production Sites:** Shenzhen, China

Shenzhen YHLO Biotech Co., Ltd. mainly produces its products in Shenzhen, China. The company has its main production facilities there, specializing in the manufacturing of diagnostic solutions. Shenzhen is known for its advanced infrastructure and its role as a technology and production hub, making it a strategic location for YHLO Biotech.

**Revenue Growth:** Estimate of 10-12% annually (2026 based on trends)

**Focus on R&D Investments:** 15% of revenue (estimated)

Shenzhen YHLO Biotech Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests a significant portion of its revenue in R&D to develop innovative diagnostic solutions and expand its product range.

Another strategic focus is on international expansion. YHLO Biotech plans to strengthen its presence in global markets, especially in regions with growing demand for diagnostic solutions. This includes expanding distribution networks and forming strategic partnerships with local players.

Additionally, the company is prioritizing the digitization of its processes and products to achieve efficiency gains and increase customer satisfaction. This strategy is intended not only to strengthen YHLO Biotech's market position but also to sustainably secure future growth.

**Main raw materials:** Biochemical reagents, plastic components, electronic parts

**Countries of origin:** USA, Germany, Japan

Shenzhen YHLO Biotech Co., Ltd. imports a variety of raw materials and components necessary for the production of their biotechnological products. The main raw materials include biochemical reagents essential for the development of diagnostic solutions. These are often sourced from the USA and Germany, as these countries are leading in the production of high-quality biochemical materials.

In addition, the company imports plastic components needed for the manufacturing of test kits and other diagnostic devices. These materials often come from Asian countries known for their cost-effective production.

Electronic parts required for the production of analytical devices are frequently imported from Japan, renowned for its advanced electronics industry.

**Market Share:** Estimated 8% in the in vitro diagnostics market (2026)
**Research and Development Ratio:** Approximately 12% of revenue (2025)
**Growth Rate in the Asian Market:** 10% annually (2025)

Shenzhen YHLO Biotech Co., Ltd. has established itself as a significant player in the field of in vitro diagnostics. The company benefits from a solid market share, especially in Asia, where it records an annual growth rate of 10%.

A key competitive advantage of YHLO is its strong focus on research and development, with about 12% of revenue being invested in this area. This enables the company to develop innovative products and continuously expand its product range.

Furthermore, YHLO benefits from a well-established supply chain and strategic partnerships, allowing the company to efficiently respond to market changes and further strengthen its position.

**Institutional Investor Share:** Estimated 35% (2026)

**Insider Buys/Sells:** No specific data available (2026)

The institutional investor share in Shenzhen YHLO Biotech Co., Ltd. is estimated to be around 35%. This is typical for companies in the biotechnology industry, which are often supported by institutional investors due to their growth potential and innovation.

Current data on insider buys or sells is not available. However, such transactions typically can indicate management's confidence in the company's future development. It is advisable to regularly check the company's disclosures and regulatory filings to stay informed about such activities.

**Market share of Shenzhen YHLO Biotech Co., Ltd.:** 4.5% (estimated, 2026)

**Top competitors and their market shares:**
1. Roche Diagnostics: 15%
2. Abbott Laboratories: 12%
3. Siemens Healthineers: 10%
4. Thermo Fisher Scientific: 8%
5. Danaher Corporation: 6%
6. Shenzhen YHLO Biotech Co., Ltd.: 4.5%
7. Bio-Rad Laboratories: 4%
8. Sysmex Corporation: 3.5%
9. Qiagen: 3%
10. PerkinElmer: 2.5%

Shenzhen YHLO Biotech Co., Ltd. holds a moderate market share of approximately 4.5%, which is relatively low compared to the industry's leading companies. However, the company has established a reputation through specialized diagnostic solutions and innovative technologies, which can be considered as a potential moat.

YHLO Biotech's moat is primarily seen in its ability to quickly adapt to new diagnostic requirements and develop niche products. In comparison to major market leaders like Roche Diagnostics and Abbott Laboratories, which have extensive research and development resources as well as a broad product portfolio, YHLO Biotech's moat is less pronounced.

The major competitors often benefit from a stronger distribution network, greater brand awareness, and more comprehensive product lines, giving them a more robust moat. Nevertheless, YHLO Biotech can strengthen its position and expand its market share through targeted innovations and strategic partnerships.

**Revenue Growth:** 18% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in the Diagnostics Industry:** 5% (2025)

Shenzhen YHLO Biotech Co., Ltd. recorded a revenue growth of 18% in 2025, driven by strong demand for its diagnostic products and expansion into international markets. The company consistently invests in research and development, with 12% of revenue allocated to this area. This indicates a strategic focus on innovation and product development.

The 5% market share in the diagnostics industry indicates that YHLO Biotech holds a significant position that could be strengthened through further expansions and product innovations. The long-term growth opportunities in the diagnostics industry, especially in the field of molecular diagnostics, are promising, increasing the potential for future profit growth.

Overall, the financial and strategic position of Shenzhen YHLO Biotech suggests that the stock could be an attractive investment opportunity for investors interested in long-term growth.

**Dividend payment:** No dividend (as of 2026)

Shenzhen YHLO Biotech Co., Ltd. has not paid any dividends so far. The company is heavily focused on research and development as well as expanding into new markets, which typically requires high reinvestment of profits.

As the company is in a growth phase and operates in a sector that requires continuous innovation, it is unlikely that a dividend will be paid in the near future. Therefore, investors should rather focus on the potential for capital gains than on dividend income.